<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04138199</url>
  </required_header>
  <id_info>
    <org_study_id>P20-097</org_study_id>
    <nct_id>NCT04138199</nct_id>
  </id_info>
  <brief_title>A Study to Assess Effectiveness and Safety of Fixed Dose Combination of Lopinavir/Ritonavir (LPV/r) in Human Immunodeficiency Virus Type 1 (HIV-1) Infected Patients After Switching From Kaletra in the Routine Clinical Settings of Russian Federation</brief_title>
  <acronym>COPI</acronym>
  <official_title>Multi-Center Observational Study to Assess Effectiveness and Safety of Fixed Dose Combination of Generic Product of Lopinavir/Ritonavir in HIV-1 Infected Patients After Switching From KaletraÂ® (Lopinavir/Ritonavir) for Administrative Reasons in the Routine Clinical Settings of Russian Federation (COPI)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a mixed prospective-retrospective, multi-center observational study to assess the
      virologic effectiveness of generic product of Lopinavir/Ritonavir (LPV/r) after switching
      from Kaletra in the routine clinical settings of Russian Federation.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Strategic Considerations
  </why_stopped>
  <start_date type="Actual">November 1, 2019</start_date>
  <completion_date type="Actual">July 8, 2020</completion_date>
  <primary_completion_date type="Actual">July 8, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants Who Meet HIV-1- RNA Viral Load &gt;50 Copies/mL, OR CD4+ T-Cell Counts &lt; 200 Cells/mm^3</measure>
    <time_frame>Up to 48 Weeks</time_frame>
    <description>Percentage of participants who meet at least one of the following composite endpoint criteria : HIV-1- Ribonucleic Acid (RNA) viral load &gt;50 copies/mL, OR Cluster of differentiation 4 (CD4+) T-cell counts &lt; 200 cells/mm3.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Indicator of Participants Who Have a Development of New or Recurrent Opportunistic Infections or HIV-Associated Malignancies OR any SAE Associated With HIV Treatment</measure>
    <time_frame>From 48 Weeks Prior to Enrollment through 48 Weeks Post Enrollment</time_frame>
    <description>Percentage of participants who meet at least one of the following composite endpoint criteria: Development of new or recurrent opportunistic infections or HIV-associated malignancies (based on physician observation and decision), OR Any Serious Adverse Event (SAE), associated with HIV treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to Failure</measure>
    <time_frame>Up to Week 48</time_frame>
    <description>Percentage of participants who meet at least one of the following composite endpoint criteria: HIV-1- RNA viral load &gt;50 copies/ml, OR CD4+ T-cell counts &lt; 200 cells/mm3, OR development of new or recurrent opportunistic infections or HIV-associated malignancies (based on physician observation and decision), OR any Serious Adverse Event (SAE), associated with HIV treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in HIV-1- RNA Viral Load Compared To The Last Measure On Kaletra Treatment</measure>
    <time_frame>Up to Week 48</time_frame>
    <description>Untransformed (Absolute) and Base-10 Logarithm Transformed Data Values of HIV-1- RNA Viral Load and The Change As Compared To The Last Measure On Kaletra Treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in CD4+ T-cell Counts Compared To The Last Measure On Kaletra Treatment</measure>
    <time_frame>Up to Week 48</time_frame>
    <description>Absolute values of CD4+ T-cell counts the change as compared to the last measure on Kaletra treatment will be summarized with descriptive statistics.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Reasons For Switching From Generic LPV/r To Other Antiretroviral Therapy (ART) For HIV Therapy OR Change In The Dosing Regimen</measure>
    <time_frame>Up to Week 48</time_frame>
    <description>Percentage of participants with different reasons for switching from generic LPV/r to other products of Antiretroviral Therapy (ART) for HIV therapy or change in the dosing regimen - medical reason (infectiveness, intolerance/toxicity, other), non-medical reasons (lack of availability of generic LPV/r, other) and other reasons.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Develop HIV Drug Resistance Of Generic LPV/r Treatment</measure>
    <time_frame>Up to Week 48</time_frame>
    <description>Percentage of participants who develop resistance to each drug will be presented.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">239</enrollment>
  <condition>HIV-1 Infection</condition>
  <arm_group>
    <arm_group_label>Participants with Human Immunodeficiency Virus-1 Infection</arm_group_label>
    <description>Human Immunodeficiency Virus-1 (HIV-1) infected and clinically stable patients on dual or triple HAART including Kaletra who switched or planned to switch to generic product of lopinavir/ritonavir</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Participants with Human Immunodeficiency Virus Type-1 (HIV-1) infection
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Human Immunodeficiency Virus Type-1 (HIV-1) infected patients on any dual or triple
             Highly Active Anti-Retroviral Therapy (HAART) with Kaletra under observation at least
             48 weeks and with two consequent plasma HIV-1 RNA levels within the last 24 weeks
             (plasma HIV-1 RNA level &lt;50 copies/mL) switched to a generic LPV/r as decided by the
             physician in the routine clinical settings within last 24 weeks from study enrollment
             date.

          -  HIV-1 infected patients with last available CD4+ T-cell count test result &gt; 200
             cells/mm3 before switching from Kaletra.

          -  Other (not LPV/r) HAART medicine components of dual or triple HIV therapy not planned
             to change by regular physician after switching to generic LPV/r.

          -  Signed Inform Consent form by patient.

        Exclusion Criteria:

          -  Participant has contraindications for the treatment with LPV/r.

          -  Legal or physical incapability of patient to sign Inform Consent form
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>AbbVie Inc.</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rep. Cen. of AIDS Profilactis /ID# 216292</name>
      <address>
        <city>Kazan</city>
        <state>Tatarstan, Respublika</state>
        <zip>420097</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rep Center for the Prev and Control of AIDS and Inf Dis of the MoH of Chuvashia /ID# 216479</name>
      <address>
        <city>Cheboksary</city>
        <zip>428003</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Reg Ctr for AIDS /ID# 216288</name>
      <address>
        <city>Chelyabinsk</city>
        <zip>454052</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GBUZ Regional Center for the P /ID# 216293</name>
      <address>
        <city>Ekaterinburg</city>
        <zip>620102</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Reg Ctr for AIDS /ID# 216295</name>
      <address>
        <city>Krasnoyarsk</city>
        <zip>660049</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ctr for AIDS Rostov /ID# 216289</name>
      <address>
        <city>Rostov on Don</city>
        <zip>344006</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samara region HIV/AIDS Center /ID# 216290</name>
      <address>
        <city>Samara</city>
        <zip>443029</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mordovian Republican Center for the Prevention and Control of AIDS /ID# 216480</name>
      <address>
        <city>Saransk</city>
        <zip>430019</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saratov Regional Center for the Prevention and Control of AIDS /ID# 216291</name>
      <address>
        <city>Saratov</city>
        <zip>410009</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GBUZ Sakhalin Regional Center for the Prevention and Control of AIDS /ID# 216478</name>
      <address>
        <city>Yuzhno-Sakhalinsk</city>
        <zip>693000</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>October 22, 2019</study_first_submitted>
  <study_first_submitted_qc>October 22, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 24, 2019</study_first_posted>
  <last_update_submitted>July 9, 2020</last_update_submitted>
  <last_update_submitted_qc>July 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Lopinavir/ritonavir (LPV/r)</keyword>
  <keyword>Kaletra</keyword>
  <keyword>Human Immunodeficiency Virus (HIV)</keyword>
  <keyword>Generic Product</keyword>
  <keyword>Highly Active Anti-Retroviral Therapy (HAART)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

